|0.5 μM||460 μM|
|In vitro||DMSO||56 mg/mL (198.31 mM)|
|Water||<1 mg/mL (<1 mM)|
|Ethanol||56 mg/mL (198.31 mM)|
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.1 mM||35.41 mL||177.05 mL||354.11 mL|
|0.5 mM||7.08 mL||35.41 mL||70.82 mL|
|1 mM||3.54 mL||17.71 mL||35.41 mL|
|5 mM||0.71 mL||3.54 mL||7.08 mL|
*The above data is based on the productmolecular weight 282.4. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|MECHANISM OF ACTION||Inhibitor|
|Storage||at -20°C 3 years Powder|
|Synonyms||NSC 242557, RG-50872, GCP 5126, SF 6847, Tyrphostin AG-17, Malonoben, Tyrphostin 9|
SU-5402 is a potent and selective vascular endothelial growth factor receptor (VEGFR) and fibroblast growth factor receptor (FGFR) inhibitor…
Erlotinib hydrochloride is a reversible tyrosine kinase inhibitor, which acts on the epidermal growth factor receptor (EGFR).
BMS 599626 is an orally bioavailable inhibitor of the HER1, HER2 and HER4 tyrosine kinases (IC50=22, 32 and 190 nM, respectively) with poten…
WHI-P180 is a potent EGFR and Cdk2 inhibitors with IC50 of 4.0 and 1.0 uM, respectively.
Lapatinib is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway.
WZ4002 is EGFR inhibitor against EGFR T790M (mutation of the gatekeeper T790 residue) which is detected in 50% of clinically resistant pati…
PD153035 is an extremely potent and specific inhibitor of the tyrosine kinase activity of EGFR.